How effective and how durable is DAA‐therapy in HCV‐infected drug users?

Abstract

See Article on Page 2244

Hepatitis C—committing the world to an eradication of the infection

“…However, PWID populations are heterogeneous (i.e., active or unstable ivdrug user vs. former PWID), and re-infection rates will increase if larger population with high-risk behavior will be treated: In Scotland, the HCV re-infection incidence rate was 34.6 per 100 py in active PWID under the age of 30 (12). Nevertheless, achievement of HCV elimination goals and especially reduction of HCV incidence rates will demand treatment in exactly these provoking populations (13). HCV dynamics among PWID suggest that an annual treatment uptake above 10% would eliminate the disease by 2030 (14).…”